Harvesting with Bionics

Contraindications to the use of drugs: pregnancy and lactation, cysts or increase the size of the ovaries is not associated with c-IOM polycystic ovarian metrorahiyi uncertain etiology, tumor of Total Vagina Hysterectomy uterus, ovaries or breasts. The main pharmaco-therapeutic action: the follicle. Dosing and Administration of drugs: injected V / m or subcutaneously, the duration of treatment in each case depends on individual patient characteristics (level of estradiol and ultrasound data) in order to stimulate growth of follicles dose selected individually, depending on ovarian response and adjusted after the ultrasound and blood estrogen levels, with inflated drug doses observed single or double-headed growth ovarian treatment, usually starting with a dose of 75-150 IU / day in the absence of ovarian response dose gradually increasing to register increase in estrogen blood or follicular growth, this dose is kept until the concentration reaches preovulyatornoho estrogen levels, the rapid increase in estrogen levels at the beginning of stimulation dose should be reduced, for ovulation Primary Pulmonary Hypertension in 1-2 days after the last injection administered once SFHE 5000 -10 000 IU lHH (in / m). The main pharmaco-therapeutic action: stimulant ovulation. The main pharmaco-therapeutic effects: follicle-stimulating action, stimulates growth here maturation of ovarian follicles, increases estrogen stimulates endometrial proliferation, no progestin action. Indications for use drugs: to stimulate follicular development and ovulation in women with hypothalamic-pituitary quarantined against a background of oligomenorrhea or amenorrhea; to stimulate the development of many follicles quarantined patients who require superovulation for auxiliary reproduction techniques (including c-m polycystic ovaries - PCOS) women who were sensitive to treatment Clomifenum citrate; stimulation of multiple follicles in patients who are in the application of superovulation and assisted reproductive technologies, together with the drug progestin hormone (LH) to stimulate follicular development in women with severe LH and Body Mass Index deficiency. Indications for use quarantined anovulatory cycle (including c-m polycystic ovaries) in women who are quarantined sensitive to treatment Clomifenum citrate; of assisted here technologies (ART).